期刊文献+

光学相干断层成像技术评价猪冠状动脉佐他莫司洗脱支架术后早期新生内膜覆盖情况 被引量:1

Evaluation of Neointimal Coverage at the Early Stage After Zotarolimus-Eluting Stents Implantation in Porcine Coronary Artery by Optical Coherence Tomography
下载PDF
导出
摘要 目的:应用光学相干断层成像(OCT)、病理和扫描电镜评价猪冠状动脉佐他莫司洗脱支架(ZES)术后早期(7天、14天、28天)新生内膜覆盖情况。方法:18只中华小型猪随机分为7天组、14天组和28天组,每组6只,每只猪于右冠状动脉置入一枚佐他莫司洗脱支架,3组实验动物分别于术后7天、14天及28天时进行OCT检查,观察支架表面新生内膜覆盖情况,并取支架段冠状动脉进行病理组织学检查及扫描电镜观察。结果:用OCT观察3个时间段支架表面新生内膜情况,7天组为(61.3±37.7)μm,14天组为(132.6±103.3)μm,28天组为(244.3±282.3)μm,3组间差异有统计学意义(P<0.001),新生内膜覆盖率7天组为(53.62±2.49)%,28天组达到(94.88±2.93)%,病理提示7天时新生内膜以炎性细胞、红细胞、血小板为主,28天时以平滑肌细胞、炎性细胞和血管内皮细胞为主。结论:OCT在支架术后7天即能清晰观察到新生内膜覆盖情况,佐他莫司洗脱支架术后28天大多数支架丝被新生内膜覆盖。 Objective:To evaluate the neointimal coverage at the early stage after zotarolimus-eluting stents (ZES) implantation in porcine coronary artery by optical coherence tomography (OCT) and scanning electron microscope image. Methods:There were 18 mini-pigs used in our study, each one received a ZES implantation in its right coronary artery. Then the animals were examined at different time points as 3 groups of 7 days, 14 days, and 28 days after the implantation, n = 6 in each group. The neointimal coverage in stent surface was examined by OCT, the histological changes in related coronary segments were observed by scanning electron microscope. Results:OCT examination showed that there were significant differences of neointimal thickness in stent surface among 3 groups as at 7 days (61.3 ±37.7 ) um, 14 days ( 132. 6± 103.3 ) um and 28 days (244. 3±282. 3 ) um,P〈0. 001 respectively. The rate of neointimal coverage also presented obvious differences among 3 groups, at 7 days ( 53.62 ± 2. 49 ) % , and at 28 days it reached (94. 88 ± 2. 93 ) %. The scanning electron microscope image indicated that 7 days after implantation,the neointima were mainly having inflammatory cells, red blood cells and platelets, while 28 days after implantation, the smooth muscle cells, inflammatory cells and endothelial cells were more observed. Conclusion:Neointima could be clearly seen by OCT at 7 days after stent implantation and most of the struts were covered with neointima at 28 days after ZES implantation.
出处 《中国循环杂志》 CSCD 北大核心 2012年第6期458-461,共4页 Chinese Circulation Journal
关键词 光学相干断层成像 佐他莫司洗脱支架 新生内膜 Optical coherence tomography Zotarolimus-eluting stent Neointima
  • 相关文献

参考文献11

  • 1Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA, 2005,293 : 2126-2130.
  • 2Aloke V. Finn, Gaku Nakazawa, et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterionscler Thromb Vasc boil,2007,27 : 1500-1510.
  • 3陈步星,马凤云,罗维,阮剑洪,谢文丽,赵希哲,孙淑红,王枫,郭旭梅,褚晓雯.光学相干断层成像评价冠状动脉内支架术后即刻支架周围组织结构改变[J].中国循环杂志,2007,22(4):271-274. 被引量:9
  • 4Bartis P, Van Soest G, Sermys PW, et al. Intracoronary optical coher- ence tomography and the evaluation of stents. Expert Rev Med De- vices. 2009.6 ( 2 _. 157-167.
  • 5王天杰,赵杰,杨跃进.冠状动脉内光学相干断层成像技术的临床应用[J].中国循环杂志,2011,26(1):72-73. 被引量:14
  • 6邱洪,高润霖,唐智荣,孟亮,兆恒,阮英卯,赵红,杨跃进,陈纪林,陈在嘉.Mytrolimus药物洗脱支架预防支架内再狭窄的实验研究[J].中华心血管病杂志,2005,33(6):561-564. 被引量:15
  • 7Kim JS, Fan C, Choi D ,et al. Different patterns of neointimal coverage between acute coronary syndrome and stable angina after various types of drug-eluting stents implantation; 9-month fallow-up optical coher- ence tomography study. Int J Cardiol,2009,46 (3) :341-346.
  • 8Guti6rrez-Chico JL, van Geuns R J, Regar E, et al. Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent vs. a fluoropoly- mer-coated everolimus-eluting stent at 13-month follow-up:an optical coherence tomography substudy from the RESOLUTE All Comers tri- M. Eur Heart J,2011,32(19) :2454-2463.
  • 9Souteyrand G, Levesque S, Ouchchane L, et al. Spatial distribution of neo-intimal hyperplasia 6 months after zotarolimus-eluting stem im- plantation, analysed by optical coherence tomography. Arch Cardiovasc Dis,2011,104(3) :147-154.
  • 10Kim JS, Kim BK, Jang IK, et al. Comparison of neointimal coverage between zotarolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography (COVER OCT). Am Heart J,2012, 163(4) :601-607.

二级参考文献23

  • 1陈步星,马凤云,罗维,谢文丽,赵希哲,孙淑红,王枫,郭旭梅,褚晓雯.光学相干断层成像在冠心病介入治疗中的应用价值[J].中华心血管病杂志,2006,34(2):130-133. 被引量:19
  • 2陈步星,马凤云,罗维.光学相干断层成像评价药物洗脱支架术后极晚期血栓形成一例[J].中华心血管病杂志,2006,34(2):180-181. 被引量:3
  • 3陈步星,马凤云,罗维,谢文丽,孙淑红,郭旭梅,王枫,赵希哲,褚晓雯.光学相干断层成像评价药物洗脱支架与金属裸支架治疗后的内膜增殖[J].中华医学杂志,2006,86(16):1102-1106. 被引量:8
  • 4Tanaka A,Imanishi T, Kitabata H, et al. Distribution and frequency of thin-capped fibroatheromas and ruptured plaques in the entire culprit coronary artery in patients with acute coronary syndrome as determined by optical coherence tomography. Am J Cardiol, 2008,102 (8) :975-979.
  • 5Jang IK, Tearney GJ, MacNeill B, et al. In vivo'characterization of coronary atherosclerotic plaque by use of optical coherence tomography. Circulation ,2005,111 ( 12 ) : 1551-1555.
  • 6Kume T, Akasaka T, Kavamoto T, et al. Assessment of coronary arterial thrombus by optical coherence tomography. Am J Cardiol, 2006,97 (12) :1713-1717.
  • 7Teamcy GJ,Jang IK,Bouma BE. Optical coherence tomography for imaging the vulnerable plaque. J Biomed Opt,2006,11 (2) :021002.
  • 8Raffel OC,Tearney G J, Gauthier DD, et al. Relationship between a systemic inflammatory marker, plaque inflammation, and plaque characteristics determined by intravascular optical coherence tomography. Arterioscler Thromb Vasc Bio1,2007,27 ( 8 ) : 1820-1827.
  • 9Matsumoto D, Shire J, Shinke T, et al. Neointimal coverage of sirolimuseluting stents at 6-month follow-up: evaluated by optical coherence tomography. Eur Heart J ,2007,28 (8) :961-967.
  • 10Garcia-Garcia HM, Gonzalo N, Regar E, et al. Virtual histology and optical coherence tomography:from research to a broad clinical application. Heart ,2009,95 ( 16 ) : 1362-1374.

共引文献35

同被引文献30

  • 1王哲颖,刘同库.雷帕霉素洗脱支架治疗无保护冠状动脉左主干严重狭窄性病变的安全性和远期效果研究[J].中国全科医学,2013,16(27):3192-3195. 被引量:10
  • 2刘幼文,金光临,刘强,罗剑峰,曾繁芳,左辉华,师姗姗,周淑英,潘楚梅,艾淑智.雷帕霉素洗脱支架治疗冠状动脉复杂病变的临床及冠状动脉造影随访观察[J].临床心血管病杂志,2006,22(7):426-428. 被引量:3
  • 3Diletti R,Serruys PW,Farooq V,et al.ABSORB II randomized controlled trial: A clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: Rationale and study design. Am Heart J.2012;164(S):6S4-663.
  • 4Stone GW,Teirstein PS,Meredith IT,et al.A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element) for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial.J Am Coil Cardiol. 2011 ;57(16):1700-1708.
  • 5Sousa JE,Costa MA,Abizaid A,et al.Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation. 2001; 103(2): 192-195.
  • 6Degertekin M,Serruys PW,Foley DP,et al.Persistent inhibition of neointimal hyperplasia after sirolimus.eluting stent impla ntation: long-term( up to 2 years )cl in ical, ang iograph ic. and intmvascular ultrasound follow-up. Circulation. 2002; 106(13): 1610-1613.
  • 7Morice MC,Serruys PW,Sousa JE,et al.A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.N Engl J Med. 2002; 346(23): 1773-1780.
  • 8Babapulle MN,Joseph L,B61 isle E, et al.A hierarchical Bayesian meta analysis of randomised clinical trials of d rug-el uting stents. Lancet. 2004; 364(9434): 583-591.
  • 9Farb A,Heller PE,Shroff S,et al.Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation. 2001;104(4):473-479.
  • 10Giannakakou P,Robey R,Foio T,et al.Low concentrations of paclitaxel induce cell type-dependent p53,p2 I and G I,G2 arrest instead of mitotic arrest:molecular determinants of paclitaxel-ind uced cytotoxicity. Oncogene .200 1 ;20(29): 3806-3813.

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部